natgillin/translations-raw huggingface dataset:
A solid cosmetic composition according to claim 9, wherein the soft vegetable butters are selected from Aloe butter, Avocado butter, Cupuacu butter, Macadamia Nut butter, Mango butter, Olive butter, Shea butter, Coconut butter, Pumpkin Seed butter, Peanut butter, And Almond butter, Coffee Bean butter, Refined butter, Hemp Seed butter, Mochacchino butter, Pistachio Nut butter, Shealoe butter and mixtures thereof. 
Kruti kozmetički pripravak prema zahtjevu 9, naznačen time što su mekani biljni maslaci odabrani od aloe maslaca, avokado maslaca, kupuaku maslaca, maslaca od makadamija oraščića, mango maslaca, maslaca od masline, shea maslaca, kokosovog maslaca, maslaca od sjemenki bundeve, kikiriki maslaca, te bademovog maslaca, maslaca od zrna kave, rafiniranog maslaca, maslaca od konoplje, Mochacchino maslaca, pistacio maslaca, Shealoe maslaca i njihovih smjesa.
creating a second conversion medium comprising at least a portion of the first propagated yeast and a second portion of the ligno-cellulosic feedstock hydrolyzate slurry; 
pripravljanja drugog pretvorbenog medija koji sadrži u najmanju ruku dio prvog trazmnoženog kvasca i drugi dio hidrolizatne suspenzije ligno-celulozne sirovine;
The polymer conjugate of claim 14 for use as an active agent in a medicament for systemic treatment. 
Polimerni konjugat prema patentnom zahtjevu 14 za uporabu kao aktivno sredstvo u lijeku za sustavno liječenje.
In case of different circuit architectures, the system according to this invention must be completely re-designed. 
U slučaju drukčije arhitekture strujnog kruga, cijeli sustav ovog izuma se mora u potpunosti redizajnirati.
Preferably, this process is such that at least one of the gel masses has a viscosity at 8° C. that is lower than 1000 mPa·s, measured with a Brookfield viscosimeter. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što najmanje jedna od masa gela ima viskoznost na 8 2C nižu od 1000 mPa.s, što je izmjereno viskozimetrom Brookfield.
The antibody for use according to any of claims 1 to 4, wherein the amyloidogenic disease characterized by amyloid deposits of AB in the brain is Alzheimer's disease. 
Humanizirano antitijelo prema bilo kojem od patentnih zahtjeva 7 do 11, za upotrebu prema tim patentnim zahtjevima, naznačeno time da je amiloidogena bolest koju karakteriziraju amiloidne naslage AB u mozgu Alzheimerova bolest.
A tablet as defined in any one of claims 7 to 9, wherein the amount of apixaban contained in the tablet is: 
Tableta za upotrebu u liječenju tromboembolijskog poremećaja, gdje tableta je tableta kao što je definirano u jednom od patentnih zahtjeva 1 do 5.
The term “polymerizable resin base” is intended to mean a composition of a constituent or a mixture of constituents such as monomer, dimers, oligomers, prepolymers, etc. 
Namjera je da termin "baza za smolu koja polimerizira" označuje sastav sastojka ili smjese sastojaka kao što je monomer, dimeri, oligomeri, prepolimeri itd.
An insulin formulation comprising insulin, dissolution agent, and zinc chelator, wherein the formulation has a pH between a pH of above 7.0 and 7.6 and is a clear aqueous solution and wherein the insulin has an enhanced transport and adsorption relative to insulin in combination with HCl and said zinc chelator, wherein the formulation does not comprise hyaluronan degrading enzyme. 
Formulacija inzulina koja sadrži inzulin, sredstvo za rastvaranje, i kelator cinka, naznačena time da formulacija ima pH između pH koja je iznad 7,0 i 7,6 i koja je bistra vodena otopina i pri čemu inzulin ima poboljšan transport i adsorpciju u odnosu na inzulin u kombinaciji s HCl i navedenim kelatorom cinka, pri čemu formulacija ne sadrži enzim koji degradira hijaluron.
Secretion and absorption by colonic crypts. Annu Rev Physiol 2005;67:471-490 . A pharmaceutical composition adapted for oral administration comprising an effective amount of at least one pharmaceutically acceptable zinc salt in combination with an effective amount of an anti-H. pylori agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient. 
Farmaceutski pripravak za primjenu u želudac bolesnika, koji sadrži učinkovitu količinu barem jedne farmaceutski prikladne cinkove soli u kombinaciji s inhibitorom protonske pumpe, po izboru u kombinaciji s farmaceutski prikladnim nosačem, aditivom ili pomoćnom tvari za uporabu za brzo povećanje pH želučanih sokova u želucu bolesnika kojemu je to potrebno na barem 3.0 u vremenu ne većem od jednog sata nakon primjene.
The capsule holder 13 (also representing an enclosing member) and the enclosing member 9 thus can selectively enclose a capsule enclosure space when transferred from an opened position into a capsule-enclosing position. 
Držač čahure 13 (koji također predstavlja 1 element za obuhvaćanje čahure) i element 9 koji obuhvaća čahuru mogu na taj način selektivno obuhvatiti prostor koji obuhvaća čahuru kada se pretvara iz otvorenog položaja u položaj kada je čahura obuhvaćena.
In a particular embodiment, the ocular disease is central geographic atrophy, non-neovascular or the dry form of age-related macular degeneration. 
4. Scilo-inozitol prema zahtjevu 1, naznačen time da senilna makularna degeneracija je suhi oblik senilne makularne degeneracije.
A method as in Embodiment 4 wherein the selected ligand is from the agonist class of ligands and the particular conformation is an agonist conformation, or the selected ligand is from the antagonist class of ligands and the particular conformation is an antagonist conformation. 
Metoda iz Zahtjeva 1-3 naznačena time da je odabrani ligand iz skupine agonista, a određena konformacija je konformacija agonista ili je odabrani ligand iz skupine antagonista i određena konformacija je konformacija antagonista.
In particular, after converting into a digital number said output voltage 90u with the A/D converter, said unit 50 subtracts its maximum value to the zero-value, calculating then the module (or absolute value) thereof, obtaining the maximum value of the actual leakage current If this maximum is greater than a limit-value, in this case the value stored at the end of phase VI, i.e. 
Posebno, nakon pretvaranja izlaznog napona 90u u digitalni broj pomoću A/D pretvarača, ta jedinica 50 oduzima njegovu maksimalnu vrijednost od nulte vrijednosti, i računa njegov modul (apsolutnu vrijednost), i tako dobiva maksimalnu vrijednost trenutne parazitne struje.
The method of claim 28, wherein said regulatory RNA is shRNA. 
Metoda dobivanja regulatornih RNA sastoji se od sljedećih koraka:
The compound of formula I of the invention can be prepared as shown in the following reaction Scheme 1 and description thereof, as well as relevant published literature procedures that may readily be used by one skilled in the art, without undue experimentation, to prepare the compounds described and claimed herein. 
Spoj formule I prema izumu se može pripremiti kao što je prikazano u slijedećoj reakcijskoj shemi 1 i njenom opisu, kao i u postupcima relevantne objavljene literature koje jednostavno može koristiti stručnjak iz tog područja tehnike, bez nepotrebnog eksperimentiranja, za pripremu spojeva koji su ovdje opisani i za koje se ovdje traži zaštita.
The pharmaceutical composition of claim 1 or 2, wherein at least one of Pea3 II, Pea3 III, Pea3 IV, and Pea3 V, or a functional portion thereof, is deleted, optionally wherein subject matter selected from a), b) and c) is deleted: 
Rekombinantni adenovirus u skladu s patentnim zahtjevom 6 ili 7, pri čemu je najmanje jedan Pea3 II, Pea3 III, Pea4 IV i Pea3 V ili njegov funkcionalni dio, izbrisan, opcionalno pri čemu predmet odabran između a), b) i c) je izbrisan:
The pellets may also contain antiadhesives, such as kaolin, talk or silicon dioxide, furthermore disintegrants or drug release promoting agents, e.g. 
Granule mogu također sadržavati antiadhezive, kao što su kaolin, talk ili silicijev dioksid, nadalje sredstva koja pomažu razgradnji ili otpuštanju lijeka, npr.
A composition according to any one of claims claims 1 to 31, 33, 35, 37, 40, 42, 45, and 47 for use in a method of treatment of type I diabetes, type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, or syndrome X. 
Pripravak u skladu s bilo kojim zahtjevom 1 do 31, 33, 35, 37, 40, 42, 45 i 47, naznačen time, da se koristi u postupku liječenja dijabetesa tip I, dijabetesa tip Il, neodgovarajuće tolerancije glukoze, inzulinske rezistencije, hiperglikemije, hiperlipidemije, hipertrigliceridemije, hiperholesterolemije, dislipidemije ili sindroma X.
the 3' or 5' terminus, depending on the position of the first region). 
3` ili 5` završetak, ovisno o položaju prve regije).
A combination according to claim 6 wherein the combination is a physically associated combination in the form of a: 
Kombinacija sukladno patentnom zahtjevu 6 pri čemu je taj pripravak fizički povezan pripravak u obliku:
alga Ecklonia comprising fat-soluble polyphenols from 50 mg to 600 mg per dosage unit, 
- alga Ecklonia koja sadrži polifenole topljive u masti od 50 mg do 600 mg po jedinici doze,
Use of a tumour associated peptide according to any one of Claims 1 to 3 or a nucleic acid according to Claim 5 or an expression vector according to Claim 6 for the manufacture of a medicament for inducing an immune response, in particular a cellular immune response, more particularly a T-cell mediated immune response against cells of solid tumours which cells express a human class II MHC molecule on their surface and present a polypeptide comprising an amino acid sequence as given in any of Claims 1 to 3. 
Upotreba tumoru pridruženih peptida prema bilo kojem od Zahtjeva 1 do 3 ili nukleinske kiseline prema Zahtjevu 4 staničnog imunološkog odgovora, specifičnije za imunološki odgovor posredovan T limfocitima protiv stanica solidnih tumora koje eksprimiraju humane MHC molekule razreda II na svojoj površini te prikazuju polipeptid koji se sastoji od slijeda aminokiselina navedenog u bilo kojem od Zahljeva 1 ili 2.
and R5 independently of one another represent hydrogen, methyl, fluorine or chlorine and 
R"i R? međusobno neovisno predstavljaju vodik, metil, fluor ili klor i
The process according to claims 10 or 11 for the preparation of a compound of formula (5) wherein both R and R' are a -CONH-CH(CH2OH)2 group, R4 is hydrogen and R5 is methyl. 
Postupak prema zahtjevima 10 ili 11 naznačen time da je za pripremanje spoja s formulom (5) pri čemu oba R i R' su skupina -CONH-CH(CH2OH), Ra je vodik i Rs je metil.
The topical cosmetic formulation according to any one of the preceding claims, wherein the concentration of the first defensin in the ready-to-use topical cosmetic formulation is about 22 ng/ml. 
Topikalna kozmetička formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je koncentracija prvog defenzina u topikalnoj kozmetičkoj formulaciji spremnoj za upotrebu otprilike 22 ng/ml.
The method according to claim 1, wherein the pharmaceutical product is selected from the group consisting of: azacytidine, belinostat, bendamustine, brentuximab vedotin, bleomycin, bortezomib, busulfan, carboplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, decitabine, deferoxamine, doxorubicin, epirubicin hydrochloride, fludarabine, fotemustine, fulvestrant, gemcitabine, idarubicin, ifosfamide, irinotecan hydrochloride, ixabepilone, melphalan, methotrexate, oxaliplatin, paclitaxel, pemetrexed, pentostatin, raltitrexed, romidepsin, temozolomide, thiotepa, topotecan, trabectedin, trastuzumab, and vinblastine. 
Upotreba u skladu s bilo kojim prethodnim patentnim zahtjevom, naznačena time, da je citotoksični lijek odabran iz skupine koju čine: azacitidin, belinostat, bendamustin, brentuksimab vedotin, bleomicin, bortezomib, busulfan, karboplatin, ciklofosfamid, citarabin, dakarbazin, daktinomicin, daunorubicin, decitabin, deferoksamin, doksorubicin, epirubicin hidroklorid, fludarabin, fotemustin, fulvestrant, gemcitabin, idarubicin, ifosfamid, irinotekan hidroklorid, iksabepilon, melfalan, metotreksat, oksaliplatin, paklitaksel, pemetreksed, pentostatin, raltitreksed, romidepsin, temozolomid, tiotepa, topotekan, trabektedin, trastuzumab i vinblastin.
wherein the hydrotreating is close-coupled to the reacting. The process of claim 9, further comprising mixing a triacylglycerides-containing oil (2) with water (10) and diatomic hydrogen (14) to form the triacylglycerides-water-diatomic hydrogen mixture (16). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da nadalje obuhvaća miješanje ulja (2) koje sadržava triacilgliceride s vodom (10) i molekularnim vodikom (14) radi dobivanja smjese triacilglicerida, vode i molekularnog vodika (16).
Methods for making prodrug and sustained released formulations of gemcitabine are well known in the art. 
Postupci dobivanja predlijeka i formulacije gemcitabina za produljeno otpuštanje dobro su poznati u struci.
The process according to any one of the preceding claims, characterized in that the reuterin comprises monomeric 3-hydroxypropionaldehyde, hydrated monomeric 3-hydroxypropionaldehyde, dimeric 3-hydroxypropionaldehyde, or cyclic forms thereof or mixtures thereof. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da reuterin sadrži monomerni 3-hidroksipropionaldehid, hidratirani monomerni 3-hidroksipropionaldehid, dimerni 3-hidroksipropionaldehid, ili njihove cikličke oblike ili njihove smjese.
A method for treating a disease selected from asthma, chronic obstructive pulmonary disease, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, comprising administering to a patient having such disease an effective amount of a compound as claimed in claim 1 . 
3. Spoj prema zahtjevu 1, za liječenje astme, kronične opstruktivne plućne bolesti, rinitisa, alergijskog sindroma dišnih puteva ili alergijskog rinobronhitisa.
mixing a neutral phospholipid, cholesterol and a buffer according to the desired formulation, then preparing a blank liposome with the desired particle size by using high-pressure homogenizer and/or extrusion equipment; 
miješanje neutralnog fosfolipida, kolesterola i pufera ovisno o željenoj formulaciji, zatim priprema praznog liposoma sa željenom veličinom čestica uporabom opreme homogenizatora s visokim pritiskom i/ili za ekstruziju;
The compounds of Set C may be prepared by one skilled in the art by the methods described above. 
Spojevi Skupine C mogu pripremiti osobe iz struke primjenom gore opisanih postupaka.
The method according to claim 10, wherein the collection comprises at least 1 × 104 antibodies or functional fragments thereof. 
Zbirka u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što zbirka sadrži najmanje 1 x 10" protutijela, ili njihovih funkcionalnih fragmenata.
The process of claim 8 wherein the further antigens comprise one or more S.pneumoniae proteins selected from the group consisting of the Poly Histidine Triad family (PhtX), Choline Binding Protein family (CbpX), CbpX truncates, LytX family, LytX truncates, CbpX truncate-LytX truncate chimeric proteins (or fusions), pneumolysin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 and Sp133. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što dodatni antigeni uključuju jedan ili više proteina iz bakterije S. pneumoniae, koji se biraju iz skupine koju čine obitelj polihistidinske trijade (PhtX), obitelj kolinski vežućeg proteina (CbpX), skraćeni CbpX, obitelj LytX, skraćeni LytX, kimerini proteim (ili fuzije) skraćeni CbpX-skraćeni LytX, pneumolizin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 i Sp133.
Use according to claim 4, wherein the compound of formula I a or its pharmaceutically acceptable salt is such that R3 represents 2-(4-trifluoromethyl-phenyl)-ethyl. 
Uporaba prema zahtjevu 4, naznačena time, da je spoj formule la ili njegova farmaceutski prihvatljiva sol takav/takva da R> predstavlja 2-(4-trifluorometil-fenil)-etil.
Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. 
Bilo koji drugi adjuvanti ili aditivi koji se obično koriste u takve svrhe kao boja, okus, konzervansi itd.
at each occurrence is independently selected from H, F, methyl, ethyl, propyl, methoxy, and ethoxy; and x is 0, 1, or 2; q is 1 or 2; 
je u svakom pojavljivanju nezavisno odabran od H, F, metil, etil, propil, metoksi, i etoksi; i x je 0, 1 ili 2; q je 1 ili 2; pod uvjetom da
A process for increasing the crystallinity of at least one solid material which is less than 100% crystalline and containing residual solvent, comprising applying ultrasound to the solid material, wherein the solid material is selected from the group consisting of an active pharmaceutical agent, a pharmaceutical excipient, and mixtures of two or more thereof, thereby increasing the crystallinity of said solid material. 
Postupak za povećanje kristaliničnosti barem jednog čvrstog materijala koji je manje od 100% kristaliničan, obuhvaća primjenu ultrazvuka na sadržajno suh čvrsti materijal koji sadrži manje od 5% težinskog udjela tekućine, pri čemu je čvrsti materijal odabran iz grupe koja se sastoji od aktivnog farmaceutskog sastojka, farmaceutskog ekscipijensa i smjesa dviju ili više od njih.
Accordingly, the invention provides a method of treating or preventing a neoplasia in a subject, the method comprising administering an effective amount of an immunoresponsive cell comprising a receptor that binds a tumor antigen and a vector encoding a co-stimulatory ligand. 
19. 'T-stanica za uporabu u liječenju ili prevenciji neoplazije kod subjekta, te T-stanica obuhvaća: kimerni receptor antigena koji veže tumorski antigen; i rekombinantni 4-1 BBL ko-stimulacijski ligand.
Finally, reduction of the 9,10-diketo taxane yields the 9,10-a,a-hydroxy taxane, as shown for example in Figure 17. 
Na kraju, redukcijom 9,10-diketo taksana dobiva se 9,10-a,a-hidroksi taksan, kao što je prikazano na primjer na slici 17.
% of one or more pharmaceutically acceptable excipients; the solid dosage unit comprising at least 0.1 mg of the estetrol component. 
pri čemu čvrsta jedinica doze sadrži najmanje 0.1 mg estetrol komponente.
The Dll4 antagonist for use according to claim 8 wherein said Dll4 antibody or antibody fragment is polyclonal or monoclonal. 
DII4 Antagonist za uporabu u skladu s patentnim zahtjevom 8, naznačen time, da je rečeno DII4 antitijelo ili fragment antitijela poliklonski ili monoklonski.
A method for treating agitation or a symptom thereof in an individual in need thereof, where the individual is a cognitively intact elderly patient, comprising administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising Form II of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and an excipient selected from the group consisting of PVP and coPVP. 
Oblik I 1-[3-(4-bromo-2-metil-2H-pirazol-3-il)-4-metoksi-fenil]-3-(2,4-difluoro-fenil)-uree u količini od oko 0.01 % do oko 5 masenih % cjelokupnog pripravka, pri čemu navedeni Oblik I je kristalni oblik koji ima uzorak rendgenske difrakcije praha koji obuhvaća vrške, u pogledu 2θ, kod oko 5.6 °, oko 7.4 °, oko 11.2 °, oko 21.1 ° i oko 25.0 °;
The method of claim 1, wherein the mouse does not express a light chain that comprises a λ constant region. 
pri čemu miš izražava antitijelo koje sadrži laki lanac koji se sastoji od preuređene humane Vλ-Jλ sekvencije i mišje Ck sekvencije.
Component A is a polyfunctional coating resin capable of forming a thermoset either by itself or together with a curing agent, B, upon heat activation. Examples of such resins (component A) are alkyd resins, polyester resins, polyacrylate resins or polymetacrylate resins with either hydroxyl, carboxylic acid or epoxy functional groups suitable for crosslinking reactions. 
Komponenta A je polifunkcionalna smola premaza, koja nakon toplinske aktivacije može tvoriti duromer i to sama ili zajedno sa sredstvom za umreživanje, B. Primjeri takovih smola (komponenta A) jesu alkilne smole, poli-esterske smole, poliakrilatne smole ili polimetakrilatne smole s hidroksilnim skupinama, sa skupinama karboksilne kiseline ili s epoksi funkcionalnim skupinama prikladnim za reakcije umreživanja.
is and solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, optionally wherein: 
je [image] ili [image] ili solvati, hidrati, tautomeri ili farmaceutski prihvatljive soli od njih.
The crenolanib or a pharmaceutically acceptable salt thereof may also be provided as a single agent in treatment of patients with the proliferative disease that is either refractory to, or has relapsed after prior treatment with a chemotherapeutic agent. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol osigurava kao jedini agens u liječenju subjekata s akutnom mijeloičnom leukemijom (AML) koja je ili refraktorna ili je relapsirala nakon prethodnog liječenja kemoterapijskim agensom.
The liposome injection according to claim 15, characterized in that the said injection is liquid injection or lyophilized powder for injection. 
Injekcija liposoma prema zahtjevu 13, naznačena time što je ta injekcija tekuća injekcija ili liofilizirani prašak za injekciju.
A compound according to claim 8 wherein R1 is C1-6-alk(en/yn)yl. 
Spoj prema patentnom zahtjevu 12, naznačen time što je R1 jednako C1-6-alk(en/in)il.
A method according to claim 1 wherein the cyclo[{4-(NH2—C2H4—NH—CO—O—)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] is an amorphous powder having a particle size less than about 5 microns. 
Mikročestice u skladu s bilo kojim prethodnim zahtjevom, naznačene time, da ciklo[(4Â«(NH>-C>Hu-NH-CO-O-)Proj-Phg-DTrp-Lys-Tyr(4-Bzl)Phe] je amorfni prašak koji ima veličinu čestica manju od oko 5 mikrona.
said compound of formula (5): being prepared by the following step A4: 
naznačen time što sadrži slijedeće korake: korak A6: pri čemu je spoj s formulom (6): e
Luxembourg: Office for Official Publications of the European Communities). 
EP 15708187.8 Datum podnošenja europske prijave patenta:
Composition according to claim 4, characterised in that it comprises tramadol in the form of tramadol hydrochloride. 
Pripravak u skladu s patentnim zahtjevom 3, naznačen time što sadrži tramadol u obliku tramadol-hidroklorida.
The crude product obtained upon solvent removal under reduced pressure is purified by column chromatography (silica gel 230-400 mesh, ethyl acetate: hexane 10:90) to get diethyl ester of cyclopent-3-ene-1, 1-dicarboxylic acid. 
Sirovi produkt dobiven prilikom uklanjanja otapala pod sniženim tlakom pročisti se kromatografijom na stupcu (silikagel veličine čestica 0,066-0,037 mm (230-400 mesh), etil-acetat/heksan 10:90) kako bi se dobilo dietilni ester ciklopent-3-en-1,1-dikarboksilne kiseline.